Ventyx Biosciences, Inc. (NASDAQ:VTYX) Receives Average Recommendation of “Moderate Buy” from Analysts

Ventyx Biosciences, Inc. (NASDAQ:VTYX) has been assigned an average rating of “Moderate Buy” from the five brokerages that are currently covering the company, Marketbeat reports. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the company. The average 12 month target price among brokers that have issued ratings on the stock in the last year is $10.00.

A number of equities analysts recently issued reports on VTYX shares. Oppenheimer reissued an “outperform” rating and issued a $9.00 price objective (down from $10.00) on shares of Ventyx Biosciences in a report on Friday, November 8th. HC Wainwright reissued a “neutral” rating and set a $6.00 target price on shares of Ventyx Biosciences in a research note on Monday, November 11th.

Insider Buying and Selling

In related news, CEO Raju Mohan purchased 261,752 shares of Ventyx Biosciences stock in a transaction dated Monday, November 25th. The stock was acquired at an average cost of $2.01 per share, with a total value of $526,121.52. Following the completion of the transaction, the chief executive officer now directly owns 2,175,028 shares of the company’s stock, valued at $4,371,806.28. This trade represents a 13.68 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider John Nuss sold 13,161 shares of the firm’s stock in a transaction that occurred on Thursday, December 19th. The stock was sold at an average price of $2.26, for a total transaction of $29,743.86. Following the sale, the insider now owns 485,701 shares of the company’s stock, valued at approximately $1,097,684.26. This represents a 2.64 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 18.18% of the company’s stock.

Institutional Investors Weigh In On Ventyx Biosciences

Institutional investors have recently modified their holdings of the stock. Palumbo Wealth Management LLC acquired a new position in shares of Ventyx Biosciences in the third quarter worth $26,000. China Universal Asset Management Co. Ltd. increased its position in Ventyx Biosciences by 64.1% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 13,592 shares of the company’s stock worth $30,000 after purchasing an additional 5,310 shares during the last quarter. SG Americas Securities LLC purchased a new stake in shares of Ventyx Biosciences during the 2nd quarter worth about $32,000. Intech Investment Management LLC acquired a new stake in shares of Ventyx Biosciences during the 3rd quarter valued at about $42,000. Finally, The Manufacturers Life Insurance Company grew its stake in shares of Ventyx Biosciences by 41.1% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 24,349 shares of the company’s stock valued at $56,000 after buying an additional 7,096 shares in the last quarter. Institutional investors and hedge funds own 97.88% of the company’s stock.

Ventyx Biosciences Trading Down 1.8 %

NASDAQ VTYX opened at $2.24 on Tuesday. The company has a 50-day moving average price of $2.30 and a two-hundred day moving average price of $2.36. The stock has a market cap of $158.39 million, a price-to-earnings ratio of -0.95 and a beta of 0.48. Ventyx Biosciences has a 52 week low of $1.67 and a 52 week high of $11.48.

Ventyx Biosciences Company Profile

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company’s lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn’s disease.